Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
- Per Hartvig HonoréAffiliated withSystems Pharmacology, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen Email author
- , Sigrid Jóhansdóttir JoensenAffiliated withSystems Pharmacology, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
- , Michelle OlsenAffiliated withSystems Pharmacology, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen
- , Steen Honoré HansenAffiliated withDepartment of Pharmacy, University of Copenhagen
- , Anders MellemgaardAffiliated withDepartment of Oncology, Herlev Hospital
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hydrophilic drugs particularly those with low plasma protein binding may accumulate in third-space fluid in the body. Cytotoxic drugs like methotrexate (MTX) cause damage in the tissue, and evacuation of the third-space fluid in pleura is strongly recommended before new dosing. Pemetrexed (PEM) is a multi-targeted antifolate similar to MTX approved for the treatment for malignant pleural mesothelioma and non-small cell lung cancer. Current recommendations for patients receiving treatment with PEM prescribe draining of the pleural fluid. This is based upon the recommendations for MTX and not directly to any specific findings relating to PEM. The recommendations are the same because PEM is an analogue of MTX; the molecular structures and pharmacokinetic parameters are similar. However, since draining the pleural fluid is painful and cancer patient are particularly susceptible to infection subsequently, it is relevant to examine the recommendations for PEM explicitly.
Eight patients treated with a 500 mg/m2 PEM combined with platinum salt were examined. Plasma samples were first collected in relation to the start of PEM infusion. Thereafter, plasma and pleura samples were taken at various times after drug infusion from each patient; in two patients, sampling was done twice but on different occasions. The quantitative determination of PEM was performed with reversed-phase high-performance liquid chromatography, and sample preparation was performed using protein precipitation with perchloric acid. Pharmacokinetic analysis was performed using a non-compartment method as well a two-compartment model.
The results were calculated from 10 samples taken from eight patients, where data from one patient point were excluded as the patient had impaired renal function, and three samples were reported as below limit of quantification. The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min. Clearance (CL) was 5.1 L/h, central volume of distribution (V central) 23.2 L and peripheral volume distribution (V peripheral) 10.6 L, and the area under the curve was 186 μg h/mL. Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L. The pleura concentrations were only half of simultaneous plasma concentrations, and elimination half-life was 3.15 h.
Pemetrexed is not likely to accumulate in the pleural fluid, and evacuation of fluid might not be necessary. Further investigation is needed to recommend no drainage of the fluid, i.e., in patients with renal impairment.
KeywordsPemetrexed Pharmacokinetics Pleura Plasma Non-small cell lung cancer
- Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
Cancer Chemotherapy and Pharmacology
Volume 74, Issue 2 , pp 349-357
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Non-small cell lung cancer
- Industry Sectors
- Author Affiliations
- 1. Systems Pharmacology, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark
- 2. Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
- 3. Department of Oncology, Herlev Hospital, Copenhagen, Denmark